Recent progress in identifying tumor antigens and understanding the host-tumor relationship have catalyzed a dramatic expansion of efforts to develop cancer vaccines. Gene transfer technologies have figured prominently in the design of many of these novel immunization schemes. This article highlights some of the key principles and controversies raised by experiments involving genetically modified tumor vaccines and speculates about future directions for investigators in this field.